Thomas J. Herzfeld Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6	Closed	-$4.94K	–	303
2023 Q3	$4.94K	Sell	6 -1	-14%	-$786	﹤0.01%	247
2023 Q2	$4.96K	Sell	7 -1	-13%	-$771	﹤0.01%	253
2023 Q1	$6.57K	Hold	8	–	–	﹤0.01%	193
2022 Q4	$5.77K	Hold	8	–	–	﹤0.01%	213
2022 Q3	$6K	Hold	8	–	–	﹤0.01%	189
2022 Q2	$5K	Hold	8	–	–	﹤0.01%	219
2022 Q1	$6K	Hold	8	–	–	﹤0.01%	217
2021 Q4	$5K	Hold	8	–	–	﹤0.01%	276
2021 Q3	$5K	Hold	8	–	–	﹤0.01%	262
2021 Q2	$4K	Buy	8 +1	+14%	+$507	﹤0.01%	294
2021 Q1	$3K	Hold	7	–	–	﹤0.01%	314
2020 Q4	$3K	Hold	7	–	–	﹤0.01%	274
2020 Q3	$4K	Hold	7	–	–	﹤0.01%	207
2020 Q2	$4K	Buy	+7	New	+$3.97K	﹤0.01%	243

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Thomas J. Herzfeld Advisors's REGN Position: Q4 2023 in Review

Thomas J. Herzfeld Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 6 shares — an estimated $4.94K sold.

Thomas J. Herzfeld Advisors first reported a position in REGN in Q2 2020 and held it in 14 quarters. The position peaked at $6.57K in Q1 2023. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

Thomas J. Herzfeld Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Thomas J. Herzfeld Advisors sold 6 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $4.94K.
Thomas J. Herzfeld Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 14 quarters.
Thomas J. Herzfeld Advisors's Regeneron Pharmaceuticals position peaked at $6.57K in Q1 2023.
1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.